Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nehal Parikh, MD
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Wilrijk, Belgium
- Novartis Investigative Site
Ulm, Germany
- Novartis Investigative Site
Milan, MI, Italy
- Novartis Investigative Site
Chuo Ku, Tokyo, Japan
- Novartis Investigative Site
Seoul, South Korea
- Novartis Investigative Site
Barcelona, Catalonia, Spain
- Novartis Investigative Site
Madrid, Spain
- Ucla
Los Angeles, California, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2018
- Primary completion
- 30 Jun 2022
- Completion
- 30 Jun 2022
- Last update posted
- 20 Jun 2024
- Registered enrollment
- 45
- Registry id
- NCT03301896
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.